NCT00848939 - Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

April 30, 2010

Conditions

Systemic Sclerosis

Interventions

DRUG

treprostinil diethanolamine

Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose

DRUG

treprostinil diethanolamine

Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID

Trial Locations (3)

Johns Hopkins Scleroderma Center, Baltimore

University of Michigan Scleroderma Program, Ann Arbor

Boston University School of Medicine Rheumatology Arthritis Center, Boston